This might be due to the possibility that FBXO7 is frequently downregulated in HCC patients by the mutation of TP53 or other tumor suppressor genes, leading to high PRMT1 protein abundance to support HCC development. The gene discussed is TP53; the disease is hepatocellular carcinoma.